<DOC>
	<DOCNO>NCT00314756</DOCNO>
	<brief_summary>To assess efficacy treat nodular basal cell carcinoma imiquimod cream initial treatment curettage</brief_summary>
	<brief_title>Treatment Nodular Basal Cell Carcinoma ( BCC ) With Imiquimod 5 % Cream After Curettage</brief_title>
	<detailed_description>The primary objective study evaluate efficacy imiquimod 5 % cream nodular BCC lesion treat 5x/week 6 week primary treatment curettage without electrodesiccation . The secondary objective study evaluate cosmetic outcome treatment lesion use modality .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Basal Cell</mesh_term>
	<mesh_term>Imiquimod</mesh_term>
	<criteria>1 . Are willing able give inform consent ; 2 . Are least 18 year age ; 3 . Are willing comply study requirement , evaluation , procedure 4 . Have 1 clinically typical , visible nodular BCC lesion meet follow criterion : primary lesion ( recurrent , previously treat biopsied ) noninfected size 0.25 1.5 cm2 locate least 1 cm eye , nose , mouth , ear , hairline exclude Hzone face clinically consistent nodular BCC histologically consistent nodular BCC histological evidence morpheaform micronodular pattern suitable treatment surgical excision easily identifiable treatable subject reliable subject representative 5 . Are free significant physical abnormality previous scar potential application site area may cause difficulty examination . 6 . Are willing stop use overthecounter retinol product product contain alpha beta hydroxyacids treatment surround area 8 hour prior treatment imiquimod cream clinic visit . 1 . Have evidence clinically significant , unstable , cardiovascular immunosuppressive , hematologic , hepatic , neurologic , renal , endocrine , collagenvascular , gastrointestinal abnormality disease may interfere completion study . 2 . Have dermatological disease treatment surround area may exacerbate treatment imiquimod cause difficulty examination . 3 . Have BCC lesion locate within 1 cm eye , nose , mouth , ear , hairline . 4 . Are pregnant screen treatment initiation visit . 5 . Have know allergy excipient study cream 6 . Have undergone surgical procedure potential treatment area within 4 week screening/treatment initiation visit . In addition , skin potential application area must heal .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2005</verification_date>
	<keyword>imiquimod cream</keyword>
	<keyword>nodular basal cell carcinoma</keyword>
	<keyword>curettage</keyword>
</DOC>